首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1542912

全球抗菌药物敏感性测试市场 - 2024-2031

Global Antimicrobial Susceptibility Testing Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

抗菌药物敏感性测试市场规模

2023年，全球抗菌药物敏感性测试市场规模达3,46,754万美元，预计2031年将达到5,4302亿美元，2024-2031年预测期间复合年增长率为5.9%。

抗菌药物敏感性测试 (AST) 是由医疗技术人员或临床实验室科学家进行的实验室技术，用于确定哪种抗菌方案对个别患者特别有效。它在很大程度上有助于评估医院、诊所和国家传染病管理和预防计画提供的治疗服务。

抗菌药物敏感性测试市场动态

全球抗菌药物敏感性测试市场的成长是由技术进步、传染患者病率上升、政府和私人组织研发资金增加以及医疗基础设施进步所推动的。

全球抗菌药物敏感性测试需求的不断增长推动了市场的成长

抗菌素抗药性（AMR）已成为全球公共卫生的主要威胁。据世界卫生组织（WHO）称，世界所有地区的抗生素抗药性正在上升至危险的高水平，导致发病率和死亡率上升。此外，世界银行估计，抗药性感染可能引发全球经济危机，到2050年每年可能有2,800万人陷入极端贫困，每年造成全球经济1兆美元的整体损失。

准确、快速地检测抗菌药物抗药性并进行适当的抗菌治疗，并结合抗菌药物管理，对于控制抗菌素抗药性的出现和传播至关重要。治疗细菌感染的最佳治疗选择依赖 AST 的结果，这是所有临床微生物实验室日常工作的一部分。报告提供了对当地抗菌药物敏感性模式的了解，帮助医疗保健专业人员选择最有效的抗生素治疗。例如，如果病原体的 AMR 率高于 20%，则不应将该药物作为感染治疗的单一经验疗法。

此外，市场参与者正在采取收购和产品推出等市场策略。例如，2022 年 4 月，BIOMERIEUX 同意收购 Specific Diagnostics。这家总部位于美国的私人公司开发了一种快速抗菌药物敏感性测试 (AST)，即 SPECIFIC REVEAL 快速 AST 系统，可直接从阳性血液培养物中提供表型 AST。此外，2020 年 2 月，Bio-Rad Laboratories, Inc. 收购了 Exact Diagnostics，这是一家诊断产品开发商和製造商，有助于确保测试结果的有效性和一致性。透过收购 Exact Diagnostics，Bio-Rad Laboratories, Inc. 可以获得移植、呼吸、病毒学、微生物学、性传播感染和媒介传播疾病领域的分子品质控制产品的全面目录。

抗菌药敏测试产品/仪器的缺点将阻碍市场的成长

然而，除了成本高之外，分子方法的主要缺点是仅透过可用探针来检测抗性基因并高估抗性，因为抗性基因不一定与抗性表型的表达相关。此外，自动化和半自动化系统具有固有的优势和局限性，且结果因抗菌药物、软体版本和卡片的不同而差异很大。因此，一些系统对于正确地对某些药物的敏感性概况进行分类是不可靠的，从而导致敏感性类别的错误分类。看来，小接种量会显着影响这些系统的结果，并报告了错误的敏感性。

COVID-19对抗菌药物敏感性测试市场的影响分析

在 COVID-19 大流行期间，与 AMR 合作伙伴合作的能力有限，导致资金减少，护理、医疗和公共卫生人员的可用性减少，影响了 AMR 的监测、预防和控制。根据临床和实验室标准研究所 (CLSI) 2020 年报告，迫切需要快速诊断来确定患者是否感染、确定病毒和细菌来源以及识别病原体及其敏感性特征。实验室可以透过快速识别可疑病原体并确定其对治疗的敏感性，在快节奏的环境中指导首次正确的临床决策。这不仅可以显着改善个人结果，而且还可以避免不必要的抗生素使用。此外，预计未来几年，消毒剂（包括洗手液和表面清洁剂）的使用增加将导致病原微生物的抗菌素抗药性率上升。

抗菌药物敏感性测试市场細項分析

自动化实验室仪器领域预计在预测期内（2024-2031）将以最快的复合年增长率成长

依产品类型：

敏感性测试盘

麦克风条

磁敏感板

自动化实验室仪器

耗材

按方法：

肉汤稀释法

快速自动化方法

圆盘扩散法

梯度扩散法

分子检测方法

按测试类型：

抗菌

抗真菌剂

抗寄生虫药

其他的

按申请：

临床诊断

药物发现与开发

其他的

按最终用户：

诊断中心和医院

製药和生物技术公司

合约研究组织 (CRO)

研究和学术机构

自动化实验室仪器领域占据最大的市场。根据 2022 年《抗生素杂誌》上发表的文章，市场上现有快速 AST 技术，包括基于微量稀释药敏测试的自动化和半自动化设备。例如，Phoenix 系统被临床微生物学实验室广泛接受并用于鑑定和抗菌药物敏感性测试。确定敏感性的原理是基于使用氧化还原指示剂（阿拉玛蓝或刃天青染料）并检测不同浓度抗菌剂存在下的细菌生长。此外，MicroScan WalkAway plus 系统可为各种革兰氏阳性和革兰氏阴性需氧细菌提供准确、快速的鑑定和药敏结果。

此外，市面上第一代 MicroScan WalkAway 系统是 AutoSCAN-3。新版本的仪器 Auto-ACAN-4 和 AutoSCAN-WalkAway 进行了改进，并使用不需要冷藏的干面板。 AutoSCAN-WalkAway 系统可侦测细菌酵素活性并可同时处理 96 个面板。先进的 AST 自动化系统的出现推动了全球市场的发展。

抗菌药物敏感性测试市场地域份额

北美地区在全球抗菌药物敏感性测试市场中占有最大的市场份额

北美在抗菌药物敏感性测试市场中占据主导地位，预计在预测期内也将呈现类似的趋势。北美抗菌药物敏感性测试市场的成长可归因于技术进步、传染病的增加、产品上市的增加以及主要参与者的存在。

据生物梅里埃组织称，美国每年发生超过 280 万例抗生素抗药性感染。抗药性细菌的出现是一种不假装的现象，抗生素使用不当会加剧和加速这种现象。该地区不断增加的抗菌药物敏感性测试推动了市场的发展。

此外，市场参与者正在采取收购和产品推出等市场策略。例如，2022 年 5 月，Accelerate Diagnostics, Inc. 宣布将其新型 Accelerate Arc 模组和 BC 套件商业化。 Accelerate Arc 模组和 BC 套件是在线离心和自动样品製备技术的新应用，它与血液培养套件一起提供清洁的微生物细胞悬浮液，以便直接转移到 MALDI 点样板。此外，Accelerate PhenoTest BC 试剂盒 AST 配置使实验室能够直接报告阳性血液培养物的鑑定和抗菌药物敏感性测试结果，比目前标准护理方法早几天。

药敏检测企业及竞争格局

抗菌药物敏感性测试市场是本地和全球公司的适度竞争的市场。为市场成长做出贡献的一些主要参与者包括生物梅里埃公司、丹纳赫公司、Becton、Dickinson and Company、Thermo Fisher Scientific Inc.、Bio-Rad Laboratories Inc.、默克集团、HiMedia Laboratories、Alifax Holding SpA、Creative Diagnostics 和共生等。主要参与者正在采取多种成长策略，例如产品发布、收购和合作，为全球抗菌药物敏感性测试市场的成长做出贡献。

例如，

2021 年 10 月，Thermo Fisher Scientific 和 Q-linea 推出了 AStar 技术，这是一种快速抗菌药敏测试 (AST) 系统，可在 6 小时内提供真正的最低抑菌浓度 (MIC)资料。传统的 AST 技术可能需要长达 72 小时才能获得结果。

生物梅里埃公司

概述：

BioMerieux SA 是一家提供微生物学解决方案的组织，该解决方案用于临床实验室以提供有效的结果，因为诊断时间和治疗效果对于感染控制、预防和管理多重抗药性以及改善患者预后至关重要。

产品组合：

VITEK 2：它是一种自动化药敏测试系统，能够确定绝大多数常规微生物（约 300 种微生物）。由于分析软体与原创的小型化消耗品相结合，因此该系统可在数小时内给出结果。此测试系统可用于各种微生物。

全球抗菌药物敏感性测试市场报告将提供约 40 多个市场资料表、45 多个数字和 200 多个（大约）页数。

Antimicrobial susceptibility testing (AST) is a laboratory technique conducted by medical technologists or clinical laboratory scientists to determine which antimicrobial regimen is particularly efficacious for individual patients. On an enormous scale, it helps evaluate treatment services delivered by hospitals, clinics, and national programs for managing and preventing infectious diseases.

Antimicrobial Susceptibility Testing Market Dynamics

The global antimicrobial susceptibility testing market growth is driven by technological advancement, a rising prevalence of infectious disease, rising funding for research and development from government and private organizations, and advancements in healthcare infrastructure.

The rising need for antimicrobial susceptibility testing across the globe drives the market growth

Antimicrobial resistance (AMR) has appeared as a major threat to public health worldwide. According to the World Health Organization (WHO), antibiotic resistance is rising to dangerously high levels in all regions of the world, leading to raised morbidity and mortality. In addition, the World Bank estimates that drug-resistant infections could induce a global economic crisis, leading to 28 million people who could be moved into extreme poverty every year by 2050, with an overall cost to the global economy of USD 1 trillion per year.

Exact and quick detection of resistance to antimicrobial drugs and following appropriate antimicrobial treatment, incorporated with antimicrobial stewardship, are crucial for controlling the emergence and spread of AMR. The best therapeutic option for treating bacterial infections relies on the results of AST, a part of the routine work of all clinical microbiological laboratories. Reports provide an understanding of local antimicrobial susceptibility patterns, helping healthcare professionals select the most effective antibiotic therapy. For instance, if the AMR rate of a pathogen is above 20%, that drug should not be administered as a single empiric therapy for infection treatment.

In addition, the market players are adopting the market strategies such as acquisition and product launches. For instance, in April 2022, BIOMERIEUX agreed to acquire Specific Diagnostics. This privately held U.S.-based company has developed a rapid antimicrobial susceptibility test (AST), SPECIFIC REVEAL Rapid AST system that delivers phenotypic AST directly from positive blood cultures. Moreover, in February 2020, Bio-Rad Laboratories, Inc. acquired Exact Diagnostics, a developer and manufacturer of diagnostic products that help ensure the validity and consistency of test results. With the acquisition of Exact Diagnostics, Bio-Rad Laboratories, Inc. has access to a comprehensive catalog of molecular quality control products in transplant, respiratory, virology, microbiology, sexually transmitted infections, and vector-borne diseases.

The drawbacks of antimicrobial susceptibility testing products/instruments will hamper the growth of the market

However, besides high costs, major drawbacks of molecular methods are the detection of the resistance genes targeted only by the available probes and overestimating resistance because the resistance gene is not necessarily associated with the expression of a resistance phenotype. In addition, automated and semi-automated systems have inherent advantages and limitations, and the results vary widely by antimicrobial drugs, software versions, and cards. Hence, some systems are unreliable for correctly categorizing susceptibility profiles for certain drugs, leading to wrong classifications of susceptibility categories. It appears that small inoculum size significantly influences the outcome of these systems, with false susceptibilities being reported.

COVID-19 Impact Analysis on Antimicrobial Susceptibility Testing Market

During the COVID-19 pandemic, the limited ability to work with AMR partnerships decreased funding, and reduced availability of nursing, medical, and public health staff affected AMR surveillance, prevention, and control. According to the Clinical and Laboratory Standards Institute (CLSI) 2020 report, there is a critical need for rapid diagnostics to determine if a patient has an infection, determine viral and bacterial sources, and identify the etiologic agent and its susceptibility profile. Labs can guide the right-first-time clinical decisions in fast-paced environments by fast identifying the suspected pathogen and determining its susceptibility to treatment. Not only can this significantly improve individual outcomes, but the approach also avoids unnecessary antibiotic use. In addition, increased use of disinfectants, including hand sanitizers and surface cleaners, is anticipated to cause inflated rates of antimicrobial resistance in pathogenic microbes in the coming years.

Antimicrobial Susceptibility Testing Market Segment Analysis

The automated laboratory instruments segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)

By Product Type:

Susceptibility Testing Disks

MIC Strips

Susceptibility Plates

Automated Laboratory Instruments

Consumables

By Method:

Broth Dilution Method

Rapid Automated Method

Disk Diffusion Method

Gradient Diffusion Method

Molecular Testing Method

By Test Type:

Antibacterial

Antifungal

Antiparasitics

Others

By Application:

Clinical Diagnosis

Drug Discovery and Development

Others

By End-User:

Diagnostic Centers and Hospitals

Pharmaceutical and Biotechnology Companies

Contract Research Organizations (CROs)

Research and Academic Institutes

The automated laboratory instruments segment accounts for the largest market share. As per the article published in Antibiotics Journal in 2022, current technologies for rapid AST are available in the market, including automated and semi-automated devices based on microdilution susceptibility testing. For instance, the Phoenix System is widely accepted and used in clinical microbiology laboratories for identification and antimicrobial susceptibility testing. The principle of determining the susceptibility is based on using an oxidation-reduction indicator (Alamar blue or resazurin dye) and detecting bacterial growth in the presence of various concentrations of the antimicrobial agent. Also, The MicroScan WalkAway plus System provides accurate and rapid identification and susceptibility results for a wide range of Grampositive and Gram-negative aerobic bacteria.

In addition, The first generation of the MicroScan WalkAway System available on the market is the AutoSCAN-3. The new versions of instruments Auto-ACAN-4 and AutoSCAN-WalkAway are improved and use dry panels that do not need refrigeration. The AutoSCAN-WalkAway system detects bacterial enzymatic activity and can process 96 panels simultaneously. The availability of advanced and automated systems for AST boosts the market worldwide.

Antimicrobial Susceptibility Testing Market Geographical Share

North America region holds the largest market share of the global Antimicrobial Susceptibility Testing market

North America dominates the market for antimicrobial susceptibility testing and is expected to show a similar trend over the forecast period. The growth of the North American antimicrobial susceptibility testing market can be attributed to technological advancements, rising infectious disease, increasing launching of products and the presence of key players.

According to the bioMerieux organization, more than 2.8 million antibiotic-resistant infections occur annually in the United States. The emergence of resistant bacteria is an unpretending phenomenon worsened and accelerated by the improper use of antibiotics. Rising antimicrobial susceptibility testing in the region drives the market.

In addition, the market players are adopting the market strategies such as acquisition and product launches. For instance, in May 2022, Accelerate Diagnostics, Inc. announced the commercialization of its new Accelerate Arc Module and BC kit. The Accelerate Arc Module and BC kit is a new application of inline centrifugation and automated sample prep techniques, which, together with the blood culture kit, provides a suspension of cleaned microbial cells for direct transfer to a MALDI spotting plate. In addition, Accelerate PhenoTest BC kit AST configuration enables laboratories to report identification and antimicrobial susceptibility test results directly from positive blood cultures days earlier than current standard-of-care methods.

Antimicrobial Susceptibility Testing Companies and Competitive Landscape

The antimicrobial susceptibility testing market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are bioMerieux S.A., Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Merck Group, HiMedia Laboratories, Alifax Holding S.p.A., Creative Diagnostics, and Synbiosis, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the global antimicrobial susceptibility testing market.

For instance,

In October 2021, Thermo Fisher Scientific and Q-linea launched ASTar Technology, a quick antimicrobial susceptibility testing (AST) system that provides true minimum inhibitory concentration (MIC) data in less than 6 hours. Conventional AST techniques might take up to 72 hours to obtain findings.

bioMerieux SA

Overview:

bioMerieux SA is an organization that provides solutions for microbiology, which is used in clinical labs to provide effective results because time-to-diagnosis and therapeutic efficacy are paramount to infection control, preventing and managing multi-drug resistance and improving patient outcomes.

Product Portfolio:

VITEK 2: It is an automated susceptibility testing system capable of determining the extensive majority of routine organisms (around 300 microorganisms). This system gives results within hours due to the combination of analysis software and an original, miniaturized consumable. This testing system is available for a various range of microorganisms.

The global antimicrobial susceptibility testing market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

1. Market Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Prevalence of Infectious Diseases
  - 4.1.1.2. Technological Advancements
- 4.1.2. Restraints:
- 4.1.3. Strict Regulatory Procedures
- 4.1.4. Opportunity
- 4.1.5. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Manual Antimicrobial Susceptibility Testing Products*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
- 7.2.3. Susceptibility Testing Disks
- 7.2.4. MIC Strips
- 7.2.5. Susceptibility Plates
7.3. Automated Laboratory Instruments
7.4. Consumables

8. By Method

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
- 8.1.2. Market Attractiveness Index, By Method
8.2. Broth Dilution Method*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
8.3. Rapid Automated Method
8.4. Disk Diffusion Method
8.5. Gradient Diffusion Method
8.6. Molecular Testing Method

9. By Test Type

9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 9.1.2. Market Attractiveness Index, By Test Type
9.2. Antibacterial*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
9.3. Antifungal
9.4. Antiparasitics
9.5. Others

10. By Application

10.1. Introduction
- 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 10.1.2. Market Attractiveness Index, By Application
10.2. Clinical Diagnosis*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
10.3. Drug Discovery and Development
10.4. Others

11. By End User

11.1. Introduction
- 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 11.1.2. Market Attractiveness Index, By End User
11.2. Diagnostic Centers and Hospitals*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
11.3. Pharmaceutical and Biotechnology Companies
11.4. Contract Research Organizations (CROs)
11.5. Research and Academic Institutes

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030, By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
- 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.2.8.1. The U.S.
  - 12.2.8.2. Canada
  - 12.2.8.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
- 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.3.8.1. Germany
  - 12.3.8.2. U.K.
  - 12.3.8.3. France
  - 12.3.8.4. Italy
  - 12.3.8.5. Spain
  - 12.3.8.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
- 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.4.8.1. Brazil
  - 12.4.8.2. Argentina
  - 12.4.8.3. Rest of South America
12.5. Asia Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
- 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.5.8.1. China
  - 12.5.8.2. India
  - 12.5.8.3. Japan
  - 12.5.8.4. Australia
  - 12.5.8.5. Rest of Asia Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
- 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

13.1. Key Developments and Strategies
13.2. Company Share Analysis
13.3. Product Benchmarking

14. Company Profiles

14.1. bioMerieux S.A.*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Key Highlights
- 14.1.4. Financial Overview
14.2. Danaher Corporation
14.3. Becton, Dickinson and Company
14.4. Thermo Fisher Scientific Inc.
14.5. Bio-Rad Laboratories Inc.
14.6. Merck Group
14.7. HiMedia Laboratories
14.8. Alifax Holding S.p.A.
14.9. Creative Diagnostics
14.10. Synbiosis (*LIST NOT EXHAUSTIVE)